News | December 09, 2023
Zepbound is now available in US for adults living with obesity
Express Scripts to add Zepbound to National Preferred Formulary
Express Scripts to add Zepbound to National Preferred Formulary
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
The product has been in-licensed from Strides and will be commercialized by Amneal
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Lack of technology transfer stands out as a formidable barrier
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated
